COMMUNIQUÉS West-GlobeNewswire
-
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
22/06/2026 -
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
22/06/2026 -
CureWise Founder and CEO Steve Brown to Speak at Aspen Ideas: Health 2026 and Launch AI-Powered Precision Oncology Platform
22/06/2026 -
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
22/06/2026 -
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
22/06/2026 -
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
22/06/2026 -
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
22/06/2026 -
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
22/06/2026 -
St. Augustine Dentist Explains Why Replacing Missing Teeth Can Support Long-Term Oral Health
22/06/2026 -
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
22/06/2026 -
Catheter Precision, Inc. Announces Allowance of Key Intellectual Property
22/06/2026 -
GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage
22/06/2026 -
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
22/06/2026 -
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
22/06/2026 -
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026 -
Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis
22/06/2026 -
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
22/06/2026 -
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
22/06/2026 -
Clariane annonce le lancement d’une offre de 333 millions d’euros d’obligations hybrides à durée indéterminée subordonnées de dernier rang en vue du refinancement de ses ODIRNANE
22/06/2026
Pages